Proteus snaps up $30M to take on heart failure
Proteus Biomedical Inc., a company developing microscopic electromechanical devices capable of one day treating or preventing congestive heart failure, brought in more than $30 million in its first call for fourth round financing. It’s original goal was $28.6 million, but CEO Andrew Thompson says the company is looking for even more money before the round’s second close, VentureWire reported.
The Redwood City, Calif.-based biotech firm is looking to strike out ahead of its competitors, CardioMEMS Inc. and CardioMetrix Inc., both of which focus on similar therapies for congestive heart failure. Right now, Proteus is working to equip existing treatments with tiny sensors that can deliver feedback on how well they’re working.
The recent funding came from new investor Pacesetter Inc., and existing contributors Adams Street Partners, the Carlyle Group, Essex Woodlands Health Ventures, Spring Ridge Ventures, and several undisclosed entities. Proteus has also been secretive about the exact total raised, saying only that it exceeded $30 million.
Update: Proteus put a finer point on its fourth round of funding on Oct. 16, reporting that it raised a total of $32 million. It also named Itochu and Medtronic as two other corporate investors.
Next Story: ChemoCentryx raises $50M, eyes bleak IPO landscape for biotech
Previous Story: Tech news network Giga Omni Media grabs another $4.5M
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.